Hospital

Despite persistent gaps in cardiovascular risk management, pharmacists are proving essential in improving LDL control, guiding statin use, and supporting evidence-based care across clinical settings.

FDA expands Arexvy RSV vaccine to at-risk adults 18-49, backed by phase 3b data—what it means for patients and pharmacists.

Although the rates of gabapentin use without a prescription were nearly double those of prescribed use, the trends are decreasing over time.

An Intermountain Health study finds atrial fibrillation present in 25% of patients with peripheral arterial disease, with major cardiovascular events occurring in 46% within 3 years.

Pharmacists have become central to titration, access, patient education, and logistics as GLP-1 use grows and cardiometabolic management evolves.

Ashlan J. Kunz Coyne drives innovative research to combat multidrug-resistant infections and enhance patient care.

Rapid RSV testing in pediatrics cuts unnecessary antibiotic use in young children with viral lung infections.

Biosimilars lower biologic costs and widen access.

Although the overall proportion of female authors in pharmacy publishing exceeds the representation of women in the pharmacy, medical, and pharmaceutical science workforces, women are more likely to be first authors than senior authors.

Stable HCV E1E2 proteins on self-assembling nanoparticles spark strong mouse antibodies, advancing a long-sought hepatitis C vaccine.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

This case report highlights pharmacists’ collaborative role in optimizing care transitions and diabetes management for a patient newly diagnosed with latent autoimmune diabetes in adults.

Pharmacists are trusted experts in medication management and clinical care who bring essential clinical expertise to PBM reform efforts.

Sibeprenlimab, a new APRIL blocker, cuts proteinuria in IgA nephropathy.

MS requires interdisciplinary collaboration, including pharmacists who can support patients throughout disease management.

A preclinical mucosal C difficile vaccine clears spores and prevents recurrence in animals, hinting at new protection for high‑risk patients.

The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."

Health-system pharmacists are reshaping care through prevention, PBM reform, and digital workflow redesign across hospitals, clinics, and retail.

Patients receiving dialysis with primary care physicians had lower rates of emergency department visits compared with those without primary care involvement.

The approval is significant for a condition that is estimated to affect fewer than 1 in 1 million individuals.

A 4-day course of a mycelium-based supplement reduced reactogenicity and sustained antibody levels for up to 6 months in COVID-naive participants.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Experts discuss guideline adoption, therapeutic advances, and team-based care.

To combat vaccine-related misinformation and disinformation, the speakers emphasize the importance of integrated education, community-led advocacy, and proactive outreach.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.

As the spring travel season approaches, more than 30 countries appear on the CDC's circulating polio alert list.